Jagsonpal Pharmaceuticals Ltd
₹
None%
- close price
About
Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]
Key Points
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Raw PDF |
Profit & Loss
Figures in Rs. Crores
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Dividend Payout % |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Figures in Rs. Crores
Equity Capital |
Reserves |
Total Liabilities |
CWIP |
Investments |
Total Assets |
Cash Flows
Figures in Rs. Crores
Net Cash Flow |
Ratios
Figures in Rs. Crores
Debtor Days |
Inventory Days |
Days Payable |
Cash Conversion Cycle |
Working Capital Days |
ROCE % |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Extract of Audited Standalone Financial Results- Copy of Newspaper Advertisement
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
7 May - Audio recording of Jagsonpal Q4 FY25 earnings call available on company website.
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
6 May - Allotment of Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022
-
Audited (Standalone) Financial Results For The Year Ended March 31 2025
6 May - Jagsonpal reports FY25 audited results, Rs. 2.5 dividend, Yash Pharma acquisition, and factory sale profit.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On May 06 2025 Along With Audited (Standalone) Financial Results
For The Quarter And Year Ended March 31 2025
6 May - Jagsonpal reports FY25 audited results, Rs.2.5 dividend, Yash Pharma acquisition, and factory sale profit.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from nse
Concalls
-
May 2025TranscriptNotesPPT
-
May 2025TranscriptNotesPPT
-
Jan 2025Transcript PPT REC
-
Oct 2024Transcript PPT
-
Oct 2024TranscriptNotesPPT REC
-
Aug 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
Business Overview:[1][2]
a) JPL provides essential medicines for women-specific healthcare needs, through Gynaecology and Orthopaedics as its focus segments.
b) It is also present in major therapeutic sub-segments viz. antibiotics, allergy management, immunity and cell protection, OTC products, dermatology and pediatrics segment
c) JPL has 17 brands amongst Top 5 brands in the molecule category. It has a pan-India presence through its strong sales team of 900+ individuals. In FY24, company generated ~47% of its revenues from its top 5 brands and ~67% from its top 7 brands